Cellnovo Group announced that the group will discontinue all manufacturing and commercial activities, effective immediately. The administrators appointed at Cellnovo Ltd., the group’s UK subsidiary, have concluded an initial analysis and have actioned a restructuring plan to focus all activities on identifying strategic partners and financial investors. As a result, a core group of existing employees from the Research and Development department will be tasked with pursuing these objectives. Production and commercial operations, including sales and marketing activities, have been discontinued. The commercial team will be working closely with partners and distributors to ensure as smooth a transition as possible for patients and their healthcare teams.